Global pharma and life sciences major Bayer and domestic drug discovery firm Curadev have signed a research collaboration and licence agreement to discover new drug candidates for treatment of lung, cardiovascular and inflammatory diseases, the companies said . The agreement is for Curadev’s stimulator of interferon genes (STING) antagonist programme.

(Economic Times)